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Economic impact of screening for X-linked
Adrenoleukodystrophy within a newborn
blood spot screening programme
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Abstract
Background: A decision tree model was built to estimate the economic impact of introducing screening for
X-linked adrenoleukodystrophy (X-ALD) into an existing tandem mass spectrometry based newborn screening
programme. The model was based upon the UK National Health Service (NHS) Newborn Blood Spot Screening
Programme and a public service perspective was used with a lifetime horizon. The model structure and
parameterisation were based upon literature reviews and expert clinical judgment. Outcomes included health,
social care and education costs and quality adjusted life years (QALYs). The model assessed screening of boys only
and evaluated the impact of improved outcomes from hematopoietic stem cell transplantation in patients with
cerebral childhood X-ALD (CCALD). Threshold analyses were used to examine the potential impact of utility
decrements for non-CCALD patients identified by screening.
Results: It is estimated that screening 780,000 newborns annually will identify 18 (95%CI 12, 27) boys with X-ALD,
of whom 10 (95% CI 6, 15) will develop CCALD. It is estimated that screening may detect 7 (95% CI 3, 12) children
with other peroxisomal disorders who may also have arisen symptomatically. If results for girls are returned an
additional 17 (95% CI 12, 25) cases of X-ALD will be identified. The programme is estimated to cost an additional
£402,000 (95% CI £399–407,000) with savings in lifetime health, social care and education costs leading to an
overall discounted cost saving of £3.04 (95% CI £5.69, £1.19) million per year. Patients with CCALD are estimated to
gain 8.5 discounted QALYs each giving an overall programme benefit of 82 (95% CI 43, 139) QALYs.
Conclusion: Including screening of boys for X-ALD into an existing tandem mass spectrometry based newborn
screening programme is projected to reduce lifetime costs and improve outcomes for those with CCALD. The
potential disbenefit to those identified with non-CCALD conditions would need to be substantial in order to
outweigh the benefit to those with CCALD. Further evidence is required on the potential QALY impact of early
diagnosis both for non-CCALD X-ALD and other peroxisomal disorders. The favourable economic results are driven
by estimated reductions in the social care and education costs.
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Background
X-linked adrenoleukodystrophy (X-ALD) is a rare gen-
etic disorder caused by a defect in the ABCD1 gene. The
disorder interrupts peroxisomal fatty acid beta oxidation
resulting in the accumulation of very long chain fatty
acids with consequent damage to tissue throughout the
body and brain. X-ALD demonstrates X-linked recessive
inheritance, with reports of incidence varying between
0.8 and 4.76 people affected per 100,000 births [1–3].
Males with X-ALD can present with adrenal insuffi-
ciency, the cerebral form of X-ALD, or progressive myel-
opathy (adrenomyeloneuropathy (AMN)). The majority
of men with X-ALD will go on to develop AMN. Most
women with X-ALD will also develop symptomatic
AMN over their lifetime, but women do not appear to
be affected by cerebral deterioration or adrenal insuffi-
ciency [4–7]. Cerebral X-ALD is the most severe pheno-
type and without treatment patients may experience
neurodegenerative decline leading to a vegetative state
and death. Studies have shown that haematopoietic stem
cell transplantation (HSCT) and more recently gene
therapy can be successful in preventing long term deteri-
oration in patients with cerebral X-ALD presenting in
childhood or adolescence (CCALD) [8–11]. However,
this benefit is dependent on being transplanted at the
first signs of neurological development with little or no
benefit to patients transplanted after this point [9–11].
There is also emerging evidence of similar benefits in
early transplanted adults [12].
Patients currently undergoing HSCT before the onset
of significant neurological symptoms, referred to as early
HSCT are most frequently identified due to family his-
tory or through presenting with adrenal insufficiency.
While screening of the extended family of X-ALD pa-
tients is currently offered it is estimated that between 5
and 18% of new patients present with a spontaneous
mutation [13, 14]. A population screening approach
using existing newborn blood spots and high throughput
tandem mass spectrometry has been shown to accurately
diagnose affected individuals and to have a high sensitiv-
ity and specificity [13, 15]. The aim of screening is to
identify patients before they become symptomatic to en-
able them to be monitored for the initial signs of
CCALD and transplanted at an optimal time. This
method of screening has been in use in New York State
since 2014 and has been found to identify patients with
other peroxisomal disorders as well as X-ALD [16, 17].
Screening programmes use criteria, often based on the
Wilson and Jungner criteria, to decide which conditions
should be screened for. These criteria often incorporate
an economic component, for example, the Wilson and
Jungner criteria state that the cost of case-finding, in-
cluding diagnosis and treatment of all patients diagnosed
should be economically balanced in relation to possible
expenditure on medical care as a whole [18]. In the
United Kingdom (UK), the National Screening Com-
mittee (NSC) criteria describe this economic require-
ment in terms of the potential cost-effectiveness of a
screening technology [19]. The aim of this study was
to address this criterion and estimate the potential
cost-effectiveness of including screening for X-ALD in
the UK National Health Service (NHS) Newborn
Blood Spot Screening Programme.
Methods
A decision analytic model was built to estimate the eco-
nomic impact of screening for X-ALD in the NHS New-
born Blood Spot Screening Programme. The model took
an NHS and personal social services (PSS) perspective,
included a lifetime horizon and discounted costs and
benefits at 3.5% [20]. The model estimated life years and
quality adjusted life years (QALYs) gained, health, social
care and special education costs. Costs were estimated
for 2014/15 with uplifting according to hospital and
community health services indices [21]. The incremental
cost effectiveness ratio (ICER) is defined as the cost per
QALY gained. The model used a decision tree structure,
shown in Fig. 1 to estimate the number of newborns that
might be identified with a positive screening result, the
distribution across the peroxisomal disorders and the
number developing CCALD and undergoing HSCT with
and without screening. It was assumed that the out-
comes of early HSCT in patients identified through
screening would be equivalent to outcomes in those
identified early without screening. Lifetime costs and
QALYs for the different outcomes with and without
screening were estimated using lifetables. The annual
number of births for the UK was estimated based on a
10 year average [22–24]. Patients identified with other
peroxisomal disorders were assumed to incur incremen-
tal costs of screening and confirmatory diagnosis, but no
health benefits or disbenefits were associated with early
diagnosis from screening. Details of all model parame-
ters are given in Table 1 and further details on the model
distribution used in the probabilistic sensitivity analysis
are given in Additional file 1.
A comprehensive, systematic search of bibliographic
databases was conducted to identify literature on X-ALD
to inform model structure and parameterisation. Infor-
mation requirements were defined prospectively, how-
ever data searching and data extraction remained
dynamic in order to reflect additional information needs
identified during model development [25]. Full details of
evidence searches and reviews are provided in the
Additional file 2.
The NHS Newborn Blood Spot Screening Programme
already uses tandem mass spectrometry hence the incre-
mental cost of including testing for X-ALD is small and
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was estimated at £0.50 per baby based on a previous
economic evaluation [26]. The review identified four
studies that reported the sensitivity and specificity of
newborn blood spot tandem mass spectrometry for
X-ALD. All studies showed either 100% sensitivity or
100% specificity or both [13, 15, 27, 28]. However, as
false negatives are likely in a population based screening
programme we assumed a sensitivity of 99.5%.
Incidence of X-ALD from four studies identified in the
review and an additional study identified after the review
that included data on incidence from the New York
screening programme were synthesised using a random
effects model in WinBugs [3, 29–32]. Studies were in-
cluded that gave both the number of cases and relevant
population figure, retrospective studies that included
both sexes fatty acid measurements were excluded due
to historic underreporting of X-ALD in women and
studies that included cases from before the adoption of
very long-chain fatty acid measurements were also ex-
cluded as they are likely to only report a minimum
estimates [33]. The Moser et al. study [32] was included
as it provided an important estimate of the incidence of
X-ALD once a screening programme has been imple-
mented of both X-ALD and the other peroxisomal con-
ditions that are identified. The incidence values from the
five studies [3, 29–32] and the synthesised incidence of 1
in 22,000 (95%Confidence Interval (CI) 1 in 33,000, 1 in
15,000) used in the model are shown in a forest plot in
Fig. 2. There is no direct evidence concerning the inci-
dence of the other peroxisomal conditions that might be
identified by screening in the UK, we therefore used the
incidence of 1 in 63,000 (95% CI 1 in 117,000, 1 in
34,000) from the New York Screening Programme [32].
The review identified 10 studies that estimated the
phenotype breakdown of X-ALD [2, 14, 29, 31, 34–39].
The studies were heterogeneous and differed in terms of
how the phenotypes were classified. Due to this no at-
tempt was made to synthesise evidence, rather the Horn
et al. [14] study of X-ALD in Norway was chosen on the
basis of study quality and relative generalisability to the
Fig. 1 X-ALD Screening Decision Tree
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UK population. This assumption was tested in a sensitiv-
ity analysis. The study of AMN by de Beer et al. [40]
was used to estimate the proportion of AMN patients
that go on to develop cerebral involvement.
The review identified 26 studies on either the natural
history or outcome following transplantation [6, 9–11,
35, 40–62]. For patients with CCALD, there is no direct
comparative evidence on survival with and without
HSCT. Survival and time to progression without trans-
plantation were estimated from the Mahmood et al.
study [11], selected from the 26 studies [6, 9–11, 35, 40–
62] as it presented data on a large cohort, 283 patients,
with follow-up of up to 30 years. The model assumed
that CCALD patients start off with mild to moderate
disease before progressing to severe CCALD indicated
by developing two or more neurological deficits with a
Table 1 Parameters Table
Parameter Mean (95% Confidence Interval) Reference
Base case parameters
Number of births per year 400,308 [22–24]
X-ALD incidence 1 in 22,361 (15,083, 33,153) [3, 29–32]
Proportion
CCALD, AMN, Addison’s/Asymptomatic
0.53 (0.36, 0.69), 0.32 (0.18, 0.49), 0.15 (0.05, 0.28) [14]
Non-X-ALD peroxisomal incidence 1 in 63,000 (33,897, 117,090) [32]
Age at presentation CCALD 7 (6.76, 7.24) [11]
Survival from onset CCALD
Weibull distribution
- shape parameter
- scale parameter
- correlation
−2.970
0.162
−0.8994
[11]
Time to CCALD progression (years) 1.6 (1.34, 1.86) [11]
Mortality risk HSCT 0.08 (0.01, 0.21) [10]
Proportion of CCALD currently undergoing early transplant (Family history) 0.33 (0.23, 0.43) [10]
Proportion ALD-DRS 0, ALD-DRS1, ALD-DRS2, ALD-DRS 3–4, after HSCT 0.62 (0.35, 0.85), 0.23 (0.05, 0.48), 0.08 (0.002, 0.26), 0.08 (0.002, 0.26) [10]
Proportion successful HSCT develop AMN 0.6 (0.19, 0.93) [65]
Sensitivity 0.995
Specificity 1
Proportion of AMN mild 0.51 (0.38, 0.64) [44]
Proportion of AMN developing adult onset cerebral X-ALD 0.63 (0.44, 0.8) [40]
Age at presentation AMN (years) 35.3 (26.7, 43.9) [40]
Time to development of adult onset cerebral X-ALD (years) 10.2 (3.3, 17.1) [40]
Survival adult onset cerebral X-ALD (years) 3.4 (0.5, 6.3) [40]
QALYs See Additional file 2
Costs See Additional file 3
Fig. 2 Forest Plot of Incidence Values. The black horizontal line represents the mean incidence and the black vertical line the 95%
confidence interval
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mean time to progression of 1.6 years. The mean sur-
vival in these patients of 19 years (16.8–21) was esti-
mated using simulated patient level data from the
Mahmood study [11, 63] with parametric extrapolation
of long term survival according to the methods recom-
mended by the National Institute for Health and Care
Excellence (NICE) Decision Support Unit [64].
For those undergoing HSCT the Peters et al. [10]
study was selected from the 26 studies identified [6, 9–
11, 35, 40–62] as it provided detailed outcomes follow-
ing HSCT, including the ALD-Disability rating scale
(ALD-DRS) and provided survival and outcomes data
based on the severity of the disease at transplant. The
model assumed that only patients with a Loes score
of < 10 undergo HSCT and that those who survive and
have a good outcome following HSCT have a normal life
expectancy as no deaths occurred post 1.5 years for those
undergoing early HSCT [9, 10]. The proportion of pa-
tients identified through a family history without screen-
ing in the Peters et al. [10] study was used to estimate the
number of those diagnosed early enough to undergo
HSCT. In the screen arm it was assumed that all CCALD
patients undergo HSCT. This assumption was explored in
a sensitivity analysis.
Estimates of patient outcomes following HSCT were
based on their functional level assessed by the ALD-DRS
before and after HSCT [10]. The outcomes of patients
with an ALD-DRS rating of 0 before HSCT were used to
model outcomes following successful HSCT [10]. Yearly
costs and QALYs were applied to the different disability
levels to estimate long term outcomes. A normal life
expectancy was assumed for those with an outcome of
ALD-DRS level 0–2 and life expectancy of
non-transplanted CCALD for those with an outcome of
ALD-DRS of 3–4.
HSCT does not prevent myelopathy in adulthood. In a
small study of five patients who had undergone success-
ful HSCT for CCALD [65], age range 18–25, three pa-
tients developed myelopathy. This rate of development
of AMN type symptoms was applied to those who had
undergone transplantation and whose outcomes were ei-
ther ALD-DRS 0 or 1. A lower age of symptom onset
(20) was used for these patients in line with the study.
Additional costs and QALY decrements were incurred
in line with AMN patients.
The model assumed normal survival for AMN and
progression per se is not modelled but patients are split
between a mild or moderate/severe form from the onset
of the disease. The model parameters were based on a
study with a cohort of 60 men that provided expanded
disability status scale (EDSS) used to estimate quality of
life and costs [44]. A second study by de Beer et al. [40]
was used to estimate a number of parameters for AMN
and adult onset cerebral X-ALD that were not provided
in the Keller et al. study [44] (see Table 1). The model
assumed that the same proportion of both the mild and
moderate/severe AMN patients go on to develop adult
onset cerebral X-ALD.
Asymptomatic and Addison’s only cases were assumed
to have normal life expectancy and morbidity. It is also
assumed that the Addison’s/Asymptomatic cases are
monitored from birth in both arms but that all AMN
cases are diagnosed symptomatically in the no-screen
arm.
No studies were identified providing direct evidence
on quality of life utilities for X-ALD patients; further-
more no suitable proxy condition was identified for
CCALD. Age specific general UK population QALYs
were used for pre-symptomatic patients, those with
Addison’s only, and for those with ALD-DRS of 0 fol-
lowing transplant [66]. Based on the description of the
ALD-DRS each state was assigned an equivalent
EuroQol Five Dimension Five Level (EQ-5D-5 L) health
state, shown in Additional file 3 [67]. QALYs for mild/
moderate CCALD were calculated as the average of
ALD-DRS1 and 2 and the QALYs for moderate/severe
CCALD were calculated as the average of ALD-DRS 3
and 4.
For patients with AMN and women with X-ALD mul-
tiple sclerosis (MS) was used as a proxy as the Expanded
Disability Status Scale (EDSS) has been used in both pa-
tient populations [40, 44]. The difference between the
mean value for the EDSS state 3 (mild AMN) and EDSS
state 6.5 (moderate/severe AMN) and the general popu-
lation norms were calculated and proportionate differ-
ences were then applied to the age specific general
population norms to give the utility decrements for each
age group [66, 68]. Further detail on the calculations of
the QALYs is provided in Additional file 3.
The costs of monitoring, diagnosis and a yearly cost of
management were estimated for each phenotype. This
was an iterative process that involved developing a re-
source use profile based on published guidelines and
guidance for patients and families with X-ALD [5, 16].
The resource use profiles were sent out for consultation
by ALD Life. The feedback from this process was used
to create final resource use descriptions presented in
Additional file 4 and were costed using appropriate
sources [21, 69–71].
The cost of diagnosis in symptomatic patients in-
cluded GP and specialist appointments associated with
the increased diagnostic journey over and above the
standard tests and consultations for all diagnosed pa-
tients as outlined in the Additional file 4. Untreated
CCALD results in substantial disability with consequent
high social care costs and education costs. In the experi-
ences of the users of ALD Life all CCALD patients require
education support often at the 1:1 or 2:1 level. Special
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education costs have been estimated based on the costs of
education of children with autism who attended, in line
with patients with CCALD, mainstream, special, and resi-
dential schools. The uplifted yearly cost is around £24,000
[72]. Social and education costs are not separated in the
model as care packages can include funding for special
education and social care. Social care costs included res-
pite care and equipment but not the costs of home adap-
tation. For those over 18 years just the social care package
and no education costs were included. Non-medical costs
such as aids and home help and transportations for AMN
and women with X-ALD were taken from a study on MS
which provided costs for EDSS state 2 and EDSS 6.5
which were used for mild AMN and moderate/severe
AMN respectively. The costs for EDSS state 2 were also
used for the women with X-ALD in the corresponding age
group of 40+ [6, 44, 68, 73]. Details of the costs are pro-
vided in Additional file 4.
Input parameters were characterised probabilistically,
see Additional file 1, and uncertainty was propagated
with Monte Carlo sampling with 100,000 replicates in
the base case and 10,000 replicates in the sensitivity ana-
lyses. A number of one-way sensitivity analyses were
undertaken to explore the impact of assumptions and
structural uncertainties in the model.
(1) The proportion of patients who develop CCALD
may be overestimated as they are the cases most
classically associated with X-ALD and there were
differences between the identified studies [2, 14, 29,
31, 34–39]. The proportion of X-ALD patients that
develop CCALD was decreased to 10%, 15%, and
20%. In each case it was estimated, based on the
base case inputs, that 69% of non-CCALD X-ALD
was AMN, and 31% was Addison’s only/
Asymptomatic.
(2) The proportion of CCALD patients in the screen
arm who undergo HSCT was reduced from 100 to
60%
(3) Scenario analyses were conducted that varied both
the proportion of patients who developed CCALD
and the proportion of CCALD patients in the
screen arm who undergo HSCT
(4) Both sexes were screened for. It is assumed based
on data from the New York Screening Programme
that the incidence in females is the same as that in
males [7, 32]. For this sensitivity analysis the study
by Engelen et al. [6] was used to model progression
of the disease in women. It was assumed that the
disease progressed with age and that all women
would become affected. EDSS scores were
converted into EQ-5D quality of life scores and the
average score for three age groups 18–39, 40–59,
and 60+ years were used in the model [6, 68, 73].
(5) NICE specifies that a lower discount rate of 1.5%
can be used for public health interventions [20].
A sensitivity analysis using the lower discount rate
was also conducted.
(6) As there is some uncertainty as to the incidence
rate in the UK the incidence rate was doubled and
halved in order to explore the impact on the
results.
(7) Patients or parents of patients with non-CCALD
X-ALD and those with other non-X-ALD disorders
may experience a disbenefit from a positive screen
results. For those with non-CCALD they or their
parents may experience anxiety about the potential
for developing CCLAD or developing the non-
treatable AMN. Patients and parents of those with
who test positive for other non X-ALD peroxisomal
disorders may also experience anxiety or distress
from being diagnosed before they become
symptomatic. It is unclear how these disbenefits
would present and if they would be limited to
anxiety or if they would present in other behavioural
changes. In order to explore and try to quantify this
uncertainty an exploratory threshold analysis was
undertaken that explored the maximum disbenefit,
expressed in QALYs, per patient per year that non-
CCALD identified patients would need to experience
in order to cancel out the benefits that accrue to
CCALD patients due to screening. The number of
cases is multiplied by the length of time they would
be expected to be asymptomatic. For non CCALD
X-ALD this is assumed to be the age of onset of
AMN (35 years), for the non-X-ALD cases we have
assumed that is will be 5 years, and for woman with
X-ALD we have assumed that is will be 50 years.
Results
The results of including screening for X-ALD in the
NHS Newborn Blood Spot Screening Programme are
presented in Tables 2 and 3. It is estimated that screen-
ing an annual UK birth cohort of approximately 780,000
newborns would identify 18 (95%CI 12, 27) males with
X-ALD. It is expected that 6 (95% CI 3, 10) of these
newborns will develop AMN, with 10 (95% CI 6, 15)
progressing to CCALD, and approximately 3 (95% CI
0.9, 6) having Addison’s only or being asymptomatic.
The model also estimates that screening will detect 7
(95% CI 3, 12) cases of other peroxisomal disorders
each year. If girls are also screened it will result in an
additional 17 (95% CI 12, 25) cases of X-ALD and
around 13 (95%CI 7, 23) cases of other peroxisomal
disorders in total.
Adding X-ALD to the screening programme as a
whole results in an increase in total discounted QALYs
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and life years per year of 82 (95% CI 43, 139) and 79
(95% CI 42, 131) respectively. The increase in QALYs
and life years is due to improvements in the outcomes
of patients with CCALD only who on average have a
gain of 8.5 QALYS per CCALD patient and a life year
gain of just over 8 years per CCALD patient.
The screening programme is estimated to cost an
additional £402,000 (95% CI £399–407,000) per year with
discounted marginal lifetime health and social care / edu-
cation costs of £256,000 (95% CI £12,000, £527,000) and
-£3.69 (95% CI -£6.27, −£1.92) million respectively, lead-
ing to an overall discounted cost saving of £3.04 (95% CI
£5.69, £1.19) million per year of screening.
As screening is estimated to result in more QALYs and
fewer costs, screening is said to dominate no screening.
The results of the probabilistic sensitivity analysis are
shown in the cost-effectiveness plane in Fig. 3. In the base
case screening dominates no screening. This means that
adding X-ALD screening into the existing screening
programme results in additional QALYs gained and lower
total discounted costs.. Across the sensitivity analyses
screening dominated no screening except when the pro-
portion of X-ALD that developed CCALD was reduced to
10%. The ICER went above the threshold of £30,000 per
QALY when both the proportion of X-ALD developing
CCALD was reduced to 10% and the proportion of
CCALD patients receiving an HSCT was reduced to 80%.
The results of the disbenefit analysis are shown in
Table 4. Results are shown for both undiscounted
QALYs and a discounted analysis which used the total
discounted incremental QALYs and discounted age at
symptomatic presentation. In the male babies only
screened analysis the disbenefit to the non CCALD pa-
tients would have to be a relatively substantial 0.84 or
0.40 per case per year in the undiscounted or discounted
analysis respectively in order to wipe out the benefit
CCALD patients derive from screening. If both sexes
were screened the disbenefit to the non CCALD patients
that would wipe out the benefit to the CCALD patients
would need to be 0.13 in the discounted analysis.
Table 2 Model estimated number of X-ALD and CCALD cases per year
Sensitivity Analyses Number of cases
X-ALD Cases 95% Confidence Interval CCALD Cases 95% Confidence Interval
Base case 18.3 (12.1,26.6) 9.7 (5.5,15.3)
Incidence rate doubled 36.5 (24.,53.2) 19.3 (11.1,31.0)
Incidence rate halved 9.1 (6.,13.2) 4.8 (2.7,7.6)
CCALD 20% of total X-ALD – – 3.6 (2.4,5.3)
CCALD 15% of total X-ALD – – 2.7 (1.8,4.)
CCALD 10% of total X-ALD – – 1.8 (1.2,2.7)
Both girls and boys screened 35.6 (23.7,51.9) – –
– Number of cases are the same as the base case
Table 3 Cost-effectiveness results
Sensitivity analyses Screening No screening Incremental
Total
Costs (m)
Total
QALYs
Total
Costs (m)
Total
QALYs
Costs
(m)
95% Confidence
Interval (m)
QALYs 95% Confidence
Interval
ICER
Base case £3.01 390 £6.44 307 -£3.04 (−£5.69, −£1.19) 82 (43, 139) Dominates
Incidence rate doubled £5.97 778 £12.88 614 -£6.50 (−£11.74, −£2.80) 164 (86, 277) Dominates
Incidence rate halved £1.51 194 £3.21 153 -£1.30 (−£2.62, −£0.39) 41 (22, 69) Dominates
CCALD 10% of total X-ALD £2.02 412 £2.21 397 £0.21 (−£0.06, £0.46) 16 (9, 24) £13,600
CCALD 15% of total X-ALD £2.13 409 £2.70 386 -£0.17 (−£0.63, £0.22) 23 (14, 36) Dominates
CCALD 60% HSCT rate £5.20 340 £6.41 307 -£0.81 (−£2.01, £0.02) 33 (15, 60) Dominates
CCALD 10% of total X-ALD and
80% HSCT rate
£2.23 407 £2.21 396 £0.42 (£0.24, £0.62) 11 (6, 17) £38,701
CCALD 15% of total X-ALD and
80% HSCT rate
£2.43 401 £2.69 385 £0.15 (−£0.18, £0.42) 16 (9, 26) £8927
CCALD 20% of total X-ALD and
80% HSCT rate
£2.65 396 £3.18 375 -£0.12 (−£0.59, £0.24) 22 (13, 34) Dominates
1.5% Discount Rate £4.59 611 £9.35 455 -£4.36 (−£7.97, −£1.81) 156 (83, 260) Dominates
Both girls and boys screened £3.27 800 £6.96 718 -£3.27 (−£5.97, −£1.36) 82 (43, 139) Dominates
m million
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Discussion
This study has attempted to address whether screening
for X-ALD is cost-effective and so fulfils the economic
criterion for a screening programme. The study suggests
that screening for X-ALD is cost saving, however prob-
lems with measurement and valuation of some of the
key benefits and harms of screening mean that it is diffi-
cult to capture the full scope of these within an eco-
nomic model. These benefits and harms also relate to
other screening criteria, in particular the evidence of
treatment benefit and the evidence on benefits and
harms from over diagnosis, overtreatment and uncertain
findings [19].
Evidence for treatment benefit for CCALD in screen-
ing comes from small observational studies in a
non-screening setting. Long term evidence on morbidity
is difficult to interpret because of the range of different
outcome measures that have been used, together with
little evidence on quality of life utilities in both trans-
planted and non-transplanted patients [9–11]. The ap-
proach taken here of mapping the ALD-DRS onto the
EQ-5D-5 L is an imperfect solution to the quality of life
issue but due to methodological and practical issues with
valuing health states in children and in those with cogni-
tive disabilities no suitable proxy conditions were found
[74–76]. The QALY estimates produced are in line with
recent studies have shown that neurological quality of
life outcomes are similar in early transplanted CCALD
patients to the general population [77, 78]. There is also
a lack of evidence concerning the impact of early
X-ALD diagnosis on patients who might go on to de-
velop Addison’s disease.
The evidence demonstrates that transplanting CCALD
patients at the first signs of cerebral involvement offers
the best outcomes in terms of both survival and morbid-
ity [9–11]. However, there currently exists no way of
identifying which X-ALD patients will go on to develop
cerebral involvement in childhood [4]. The need to
intervene before there are significant symptoms and the
lack of other treatment options brings with it the poten-
tial for over or under-treatment if there is variation in
the implementation of clinical guidelines [79]. This
could also be exacerbated if CCALD patients or fam-
ilies do not follow monitoring protocols or do not
consent to transplantation, a procedure with poten-
tially severe complications.
Fig. 3 Cost-Effectiveness Plane. Each of the blue diamonds
represents one of the 100,000 model runs. Costs in () represent
model runs where screening is estimated to be cost saving
Table 4 Results of the Disbenefit Analysis
Male babies only screened Both sexes screened
Undiscounted Discounted Undiscounted Discounted
Non CCALD X-ALD 8.61 8.61 8.61 8.61
Age of symptomatic presentation 35.00 20.55 35.00 20.55
Person years without diagnosis 301.34 176.95 301.34 176.95
Non X-ALD disorders 6.68 6.68 13.04 13.04
Age of symptomatic presentation 5.00 4.66 5.00 4.66
Person years without diagnosis 33.39 31.11 65.21 60.76
Number of cases of X-ALD in females – – 17.36 17.36
Age of symptomatic presentation – – 50.00 24.11
Person years without diagnosis – – 867.96 418.60
Total person years without diagnosis 334.73 208.06 1234.52 656.32
Total incremental QALYs from screening 280.15 82.42 279.78 82.30
Maximum QALY decrement per non CCALD case per year 0.84 0.40 0.23 0.13
– No cases in females when only male babies are screened
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The quality of life and behavioural impacts of receiving
an early diagnosis of X-ALD particularly for those who
do not develop CCALD are also not well understood or
valued. This is also the case for those diagnosed with
other peroxisomal disorders. This is particularly relevant
as despite recent studies investigating transplantation in
adult onset cerebral ALD, there are no established treat-
ment options for non-CCALD patients and therefore
screening is currently unlikely to improve clinical out-
comes in these patients outside of improved adrenal
monitoring [12, 16, 79]. The issue is also particularly
relevant if both sexes are screened as this increases the
number of non-CCALD patients identified.
Where possible the impact of these issues has been ex-
plored through sensitivity, probabilistic sensitivity and
threshold analyses. The results of which suggest that the
results are robust to the assumptions made in the model.
In addition some of these evidence gaps, such as the
types and number of other peroxisomal disorders identi-
fied, will be addressed by the results coming out of the
New York X-ALD screening programme and other
implementing sites [16, 79]. In the longer term the exist-
ing X-ALD screening programmes will also be able to
address other evidence gaps such as the feasibility and
efficacy of monitoring, transplantation protocols and dis-
ease natural history. Specific studies may also need to be
undertaken in order to fully understand the impact of
identifying those with non-CCALD, improve the evi-
dence on the quality of life and resource use of those
currently living with CCALD and understand the quality
of life and resource impact of the diagnostic journey in
symptomatic patients.
There are methodological issues associated with meas-
uring and valuing many of the potential benefits and
harms of newborn screening. For instance, impacts on
families and carers, including future family planning,
measuring and valuing quality of life in children, espe-
cially those with cognitive disabilities, and estimating the
impact on families of incidental findings arising through
screening [74–76, 80]. Not all of these issues are covered
by current guidelines on economic evaluation of new-
born screening interventions [81] and further methodo-
logical work is required to improve the quality and
scope of future economic evaluations.
Conclusion
This study estimates that including screening for X-ALD
in a tandem MS based screening programme such as the
UK NHS Newborn Blood Spot Screening Programme
would result in an increase in QALYs and a decrease in
total discounted health, social care and education costs.
The results are driven by the reduction in social care
costs and the increase in QALYs for CCALD patients.
Sensitivity analyses suggest that the results are sensitive
to the proportion of patients with X-ALD that go on to
develop CCALD. Threshold analyses suggest that any
potential disbenefits arising for those with non-CCALD
conditions would need to be substantial in order to out-
weigh the benefit to those with CCALD. However the
uncertainties associated with measuring and valuing the
benefits and harms of screening in the X-ALD popula-
tion need to be addressed in order to fully demonstrate
that the economic criteria can be fulfilled.
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